LUCD vs VCYT
LUCD: Lucid Diagnostics is a cancer prevention company providing a non-invasive, office-based diagnostic test for the early detection of esophageal precancer and cancer in at-risk GERD patients. VCYT: Veracyte is a genomic diagnostics company transforming cancer care with advanced, high-value testing platforms across the patient journey from diagnosis to monitoring.
Side-by-side fundamentals
| Metric | LUCD | VCYT | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $0.6501 | $43.60 | |
| Market cap | $132M | $3.5B | |
| P/E as of 2026-10-08 | n/a | 31.08 | |
| Net margin | -1047.6% | +12.8% | VCYT higher |
| Gross margin | +100.0% | +70.1% | LUCD higher |
| Operating margin | -1059.6% | +11.2% | VCYT higher |
| ROE FY2025, SEC XBRL | -530.4% | +5.1% | VCYT higher |
| ROA FY2025, SEC XBRL | -143.4% | +4.7% | VCYT higher |
| Debt / equity as of 2026-09-03 | 6.30 | 0.00 | VCYT lower |
| Revenue growth (YoY) as of 2026-09-03 | +23.0% | +17.3% | LUCD higher |
| Revenue CAGR (3y) SEC XBRL | +105.6% | +20.4% | LUCD higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.86 | 1.32 | |
| 1-year return as of 2026-10-08 close | -46.7% | +24.2% | VCYT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.